BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 31213769)

  • 1. Frequency, clinical features and differential response to therapy of concurrent
    Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
    Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
    J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series.
    Shin HJ; Kho BG; Kim MS; Park HY; Kim TO; Kim YI; Lim SC; Park CK; Kim YC; Choi YD; Oh IJ
    Medicine (Baltimore); 2019 Mar; 98(9):e14699. PubMed ID: 30817606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
    Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J
    BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Yu Y; Ou Q; Wu X; Bao H; Ding Y; Shao YW; Lu S
    Lung Cancer; 2019 Jan; 127():19-24. PubMed ID: 30642546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer.
    Wang Z; Zhang X; Bai H; Zhao J; Zhuo M; An T; Duan J; Yang L; Wu M; Wang S; Wang Y; Wu Y; Wang J
    Oncology; 2012; 83(5):248-56. PubMed ID: 22964709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
    Shaw AT; Yeap BY; Mino-Kenudson M; Digumarthy SR; Costa DB; Heist RS; Solomon B; Stubbs H; Admane S; McDermott U; Settleman J; Kobayashi S; Mark EJ; Rodig SJ; Chirieac LR; Kwak EL; Lynch TJ; Iafrate AJ
    J Clin Oncol; 2009 Sep; 27(26):4247-53. PubMed ID: 19667264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
    Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
    Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
    Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
    Hu W; Liu Y; Chen J
    Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
    Wu SG; Kuo YW; Chang YL; Shih JY; Chen YH; Tsai MF; Yu CJ; Yang CH; Yang PC
    J Thorac Oncol; 2012 Jan; 7(1):98-104. PubMed ID: 22124476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
    Miyanaga A; Shimizu K; Noro R; Seike M; Kitamura K; Kosaihira S; Minegishi Y; Shukuya T; Yoshimura A; Kawamoto M; Tsuchiya S; Hagiwara K; Soda M; Takeuchi K; Yamamoto N; Mano H; Ishikawa Y; Gemma A
    BMC Cancer; 2013 May; 13():262. PubMed ID: 23714228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice.
    Jamme P; Descarpentries C; Gervais R; Dansin E; Wislez M; Grégoire V; Richard N; Baldacci S; Rabbe N; Kyheng M; Kherrouche Z; Escande F; Copin MC; Cortot AB
    Clin Lung Cancer; 2019 Jul; 20(4):297-304.e1. PubMed ID: 31147208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Cai C; Tang Y; Li Y; Chen Y; Tian P; Wang Y; Gong Y; Peng F; Zhang Y; Yu M; Wang K; Zhu J; Lu Y; Huang M
    Lung Cancer; 2021 Feb; 152():104-108. PubMed ID: 33444901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.